NewLink’s HyperAcute Program In Limbo After Pancreatic Trial Blow-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says it is evaluating what to do with its HyperAcute vaccine candidates in various tumor types, as focus shifts toward IDO programs.